Dr. Marco Müller takes over the management of ABX
Radeberg, August 13, 2024. Marco Müller (PhD) took over the General Management of ABX on August 1st, 2024. He succeeds the founder and previous sole Managing Director Peter Moll (PhD), who will remain with the company as Co-Managing Director in an advisory capacity until the end of the year to ensure a smooth transition.
Marco Müller has been part of the ABX team since the early days and has very successfully built up the Radiochemistry department. "Marco Müller understands the business of ABX like no other and is therefore a logical choice for my succession," explains Peter Moll.
"The entire ABX workforce would like to thank Peter Moll for his tireless and extremely successful work in building and scaling ABX into a leading global provider of radiopharmaceutical products and solutions," says Marco Müller. "Now with over 350 employees at the Radeberg site, we continue to be a fast-growing, very healthy and established employer. And we believe we are ideally positioned to continue our success story."
With a view to future growth targets, ABX continues to focus on the Radeberg site. For example, the new radiochemistry building at the Heinrich-Gläser-Street with a very powerful 30 MeV cyclotron is currently being completed. It complements the existing radiochemistry building and significantly increases the available research and production space for radiopharmaceutical drugs. Under Dr. Müller, the ABX thus also stands for dynamic expansion in the development and production of radiopharmaceuticals, which are predicted to have a rapidly growing market potential.
Most recently, Dr. Müller and various ABX departments successfully advanced the development of the patent-protected diagnostic agent Radelumin®, for which ABX received marketing approval for Germany and 8 other European countries in 2023.
Press Release
Marco Müller has been part of the ABX team since the early days and has very successfully built up the Radiochemistry department. "Marco Müller understands the business of ABX like no other and is therefore a logical choice for my succession," explains Peter Moll.
"The entire ABX workforce would like to thank Peter Moll for his tireless and extremely successful work in building and scaling ABX into a leading global provider of radiopharmaceutical products and solutions," says Marco Müller. "Now with over 350 employees at the Radeberg site, we continue to be a fast-growing, very healthy and established employer. And we believe we are ideally positioned to continue our success story."
With a view to future growth targets, ABX continues to focus on the Radeberg site. For example, the new radiochemistry building at the Heinrich-Gläser-Street with a very powerful 30 MeV cyclotron is currently being completed. It complements the existing radiochemistry building and significantly increases the available research and production space for radiopharmaceutical drugs. Under Dr. Müller, the ABX thus also stands for dynamic expansion in the development and production of radiopharmaceuticals, which are predicted to have a rapidly growing market potential.
Most recently, Dr. Müller and various ABX departments successfully advanced the development of the patent-protected diagnostic agent Radelumin®, for which ABX received marketing approval for Germany and 8 other European countries in 2023.
Press Release